Edgewise Therapeutics, Inc. Overview
Pro stress-test →Edgewise Therapeutics is a biopharmaceutical company that discovers, develops, and commercializes therapies for the treatment of muscle disorders. The company underwent a major strategic pivot in June 2026 with the sale of sevasemten and its muscular dystrophy business to Servier for $1.55 billion in upfront cash and up to $1.1 billion in milestone payments, positioned to close in Q3 2026. Following this transaction, Edgewise will become a cardiovascular-focused company with a pipeline comprising EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for heart failure with preserved ejection fraction, and EDG-003 for an undisclosed target.
Strategic Profile
Pro stress-test →By concentrating on therapies that directly target the root causes of musculoskeletal disorders, the company establishes itself as a specialized player within the biotech industry, with its research-focused operational model dedicated to addressing unmet medical needs. The muscular dystrophy asset sale meaningfully strengthens Edgewise's balance sheet, providing enhanced financial flexibility and sharpening the company's strategic focus to accelerate its cardiovascular pipeline.
Competitive Landscape
Pro stress-test →Edgewise competes in the rare muscle disorder and cardiovascular drug development space against established biotech and pharma players with cardiac programs. The company positions itself as a specialized player by targeting the root causes of musculoskeletal and cardiovascular disorders. Key competitive areas include hypertrophic cardiomyopathy and heart failure therapeutics, where other biotech and pharma companies are also advancing small-molecule and biologic candidates. Post-transaction, Edgewise's focus narrows to cardiovascular indications, allowing concentration against incumbent cardiac programs.
Industry Context
Edgewise Therapeutics, Inc. operates in Cardiovascular small-molecule drug development.
Key facts
Founded: N/A · Headquarters: Boulder, US · Employees: N/A · Revenue: $0 (pre-revenue clinical stage) · Market cap: N/A